Shares of Twist Bioscience Corp (TWST) surged over 5% in pre-market trading on Monday, following the company's better-than-expected fiscal first-quarter 2025 earnings results and an optimistic revenue outlook for the current quarter. The stock rally reflects investors' positive sentiment toward the synthetic biology and genomics company's strong performance and growth prospects.
For the quarter ended December 31, 2024, Twist Bioscience reported a net loss of $0.53 per share, narrower than analysts' consensus estimate of a $0.62 loss per share. Revenue came in at $88.7 million, surpassing the FactSet consensus of $87 million.
Looking ahead, the company guided for fiscal second-quarter 2025 revenue in the range of $91 million to $93 million, exceeding Wall Street's expectations of $90.9 million. This upbeat guidance underscores Twist Bioscience's confidence in sustaining its growth momentum amid rising demand for its synthetic DNA-based products and services.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.